BLFS vs XRAY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

BLFS

37.1
AI Score
VS
XRAY Wins

XRAY

57.9
AI Score

Investment Advisor Scores

BLFS

37score
Recommendation
AVOID NEW MONEY

XRAY

58score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BLFS XRAY Winner
Forward P/E 238.0952 6.3291 XRAY
PEG Ratio 65.3833 0.633 XRAY
Revenue Growth 21.5% -4.1% BLFS
Earnings Growth -13.9% 15.2% XRAY
Tradestie Score 37.1/100 57.9/100 XRAY
Profit Margin 54.4% -15.0% BLFS
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD XRAY

Relative Price Performance (Last 90 Days)

BLFS 1M: +5.0% · 3M: +35.8% XRAY 1M: -23.4% · 3M: -29.8%

Current Technical Phase

BLFS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (10.2% over 20 days), RSI 56

RSI (14): 55.9 · Price: $37.73

XRAY

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 28

RSI (14): 27.5 · Price: $8.65

Fundamentals Snapshot

Metric BLFS XRAY
Market Cap — —
Forward P/E 111.5 5.8
Trailing P/E 38.9 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.6% 0.5%
Operating Margin 0.1% 0.1%
EPS 1.00 -2.69
Dividend Yield — 0.04%

Frequently Asked Questions

Based on our detailed analysis, XRAY is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.